DK0669986T3 - Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr - Google Patents

Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr

Info

Publication number
DK0669986T3
DK0669986T3 DK94901599T DK94901599T DK0669986T3 DK 0669986 T3 DK0669986 T3 DK 0669986T3 DK 94901599 T DK94901599 T DK 94901599T DK 94901599 T DK94901599 T DK 94901599T DK 0669986 T3 DK0669986 T3 DK 0669986T3
Authority
DK
Denmark
Prior art keywords
atg
expression
disclosed
nucleotide
pyxx
Prior art date
Application number
DK94901599T
Other languages
English (en)
Inventor
Mitchell E Reff
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/147,696 external-priority patent/US5648267A/en
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Application granted granted Critical
Publication of DK0669986T3 publication Critical patent/DK0669986T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Image Analysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK94901599T 1992-11-13 1993-11-12 Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr DK0669986T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97769192A 1992-11-13 1992-11-13
US08/147,696 US5648267A (en) 1992-11-13 1993-11-03 Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
PCT/US1993/011221 WO1994011523A2 (en) 1992-11-13 1993-11-12 Fully impaired consensus kozac sequences for mammalian expression

Publications (1)

Publication Number Publication Date
DK0669986T3 true DK0669986T3 (da) 2003-07-28

Family

ID=26845148

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94901599T DK0669986T3 (da) 1992-11-13 1993-11-12 Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr

Country Status (8)

Country Link
US (3) US5733779A (da)
EP (1) EP0669986B1 (da)
AT (1) ATE236987T1 (da)
CA (1) CA2149326C (da)
DE (2) DE69332859T2 (da)
DK (1) DK0669986T3 (da)
ES (1) ES2088838T3 (da)
PT (1) PT669986E (da)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6086527A (en) 1998-04-02 2000-07-11 Scimed Life Systems, Inc. System for treating congestive heart failure
US7820161B1 (en) * 1999-05-07 2010-10-26 Biogen Idec, Inc. Treatment of autoimmune diseases
MXPA03002262A (es) * 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
US20050144655A1 (en) * 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
CN1526011A (zh) * 2001-07-10 2004-09-01 IDECҩ�﹫˾ 抑制凋亡过程及改善细胞性能
IL161988A0 (en) 2001-11-16 2005-11-20 Corporation Idec Pharmaceutica Polycistronic expression of antibodies
AU2003213270A1 (en) * 2002-02-25 2003-09-09 Intronn, Inc. Trans-splicing mediated imaging of gene expression
US20040172667A1 (en) * 2002-06-26 2004-09-02 Cooper Richard K. Administration of transposon-based vectors to reproductive organs
US20040235011A1 (en) * 2002-06-26 2004-11-25 Cooper Richard K. Production of multimeric proteins
US7527966B2 (en) * 2002-06-26 2009-05-05 Transgenrx, Inc. Gene regulation in transgenic animals using a transposon-based vector
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT2314629E (pt) * 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
EP1572994B1 (en) 2002-12-20 2007-02-21 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
CA2514062A1 (en) * 2003-01-27 2004-08-12 Biogen Idec Ma Inc. Compositions and methods for treating cancer using igsf9 and liv-1
HUE025347T2 (en) 2003-03-19 2016-02-29 Biogen Ma Inc NOGO receptor binding protein
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP2960251A1 (en) * 2003-05-09 2015-12-30 Duke University CD20-specific antibodies and methods of employing same
EP2395017A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2374526T3 (es) 2003-09-04 2012-02-17 Medarex, Inc. Vector de expresión.
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
ES2646560T3 (es) 2004-01-20 2017-12-14 Merus N.V. Mezclas de proteínas de unión
ES2395094T3 (es) 2004-06-24 2013-02-08 Biogen Idec Ma Inc. Tratamiento de afecciones que implican la desmielinización
JP5060293B2 (ja) 2004-08-03 2012-10-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド 神経機能におけるｔａｊ
ES2384391T3 (es) * 2004-11-08 2012-07-04 Chromagenics B.V. Selección de células hospedantes que expresan proteína a altos niveles
US20060195935A1 (en) 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
PL1809750T3 (pl) * 2004-11-08 2012-08-31 Chromagenics Bv Selekcja komórki gospodarza eksprymującej białko na wysokich poziomach
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
EP2311880A3 (en) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
PT1904104E (pt) 2005-07-08 2013-11-21 Biogen Idec Inc Anticorpos sp35 e suas utilizações
MX2008005764A (es) 2005-11-04 2008-11-18 Biogen Idec Inc Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
NZ569428A (en) 2005-12-02 2012-11-30 Biogen Idec Inc Treatment of conditions involving demyelination with a Sp35 antagonist
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
DK1981902T3 (da) 2006-01-27 2015-10-05 Biogen Ma Inc Nogo-receptor-antagonister
US7612178B2 (en) * 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
EP3239175A1 (en) 2007-01-05 2017-11-01 University of Zurich Method of providing disease-specific binding molecules and targets
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
SI2068887T1 (sl) 2007-01-09 2014-06-30 Biogen Idec Ma Inc. SP35 protitelesa in njihova uporaba
JP5492567B2 (ja) 2007-02-02 2014-05-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 髄鞘形成およびオリゴデンドロサイト分化を促進するためのセマフォリン６ａの使用
EP2197490A2 (en) * 2007-08-28 2010-06-23 Biogen Idec MA, Inc. Compositions that bind multiple epitopes of igf-1r
WO2009032145A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
US20090291088A1 (en) * 2008-04-11 2009-11-26 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
TW201438738A (zh) 2008-09-16 2014-10-16 Genentech Inc 治療進展型多發性硬化症之方法
WO2010036979A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of interferon
WO2010036978A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of growth hormone
WO2010036976A2 (en) * 2008-09-25 2010-04-01 Transgenrx, Inc. Novel vectors for production of antibodies
NZ593964A (en) 2008-12-19 2012-12-21 Univ Zuerich Human anti-alpha-synuclein autoantibodies
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
KR101160048B1 (ko) 2009-03-31 2012-06-26 (주)셀트리온 목적 단백질 고발현 세포주의 선별 방법
US9150881B2 (en) * 2009-04-09 2015-10-06 Proteovec Holding, L.L.C. Production of proteins using transposon-based vectors
CN102648285A (zh) 2009-08-06 2012-08-22 Cmc依科斯生技制品公司 用于改进重组蛋白表达的方法
BR112012020102A2 (pt) 2010-02-10 2016-11-29 Immunogen Inc anticorpos cd20 e usos dos mesmos.
CA2804280A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Chimeric clotting factors
NZ609984A (en) 2010-10-11 2015-05-29 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
WO2012080518A1 (en) 2010-12-17 2012-06-21 Neurimmune Holding Ag Human anti-sod1 antibodies
US9580493B2 (en) 2011-06-23 2017-02-28 Biogen International Neuroscience Gmbh Anti-α synuclein binding molecules
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
CA2873623C (en) 2012-05-14 2021-11-09 Biogen Idec Ma Inc. Lingo-2 antagonists for treatment of conditions involving motor neurons
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
EP2906240A2 (en) 2012-10-09 2015-08-19 Biogen MA Inc. Combination therapies and uses for treatment of demyelinating disorders
EP3792278A3 (en) 2012-12-21 2021-05-26 Biogen MA Inc. Human anti-tau antibodies
JP6407165B2 (ja) 2012-12-31 2018-10-17 ニューリミューン ホールディング エイジー ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体
SI3889173T1 (sl) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
BR112017006598A2 (pt) 2014-09-30 2018-04-17 Neurimmune Holding Ag anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
MX2017009038A (es) 2015-01-08 2017-10-25 Biogen Ma Inc Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
WO2017024060A1 (en) 2015-08-03 2017-02-09 Biogen Ma Inc. Factor ix fusion proteins and methods of making and using same
PL3411478T3 (pl) 2016-02-01 2022-10-03 Bioverativ Therapeutics Inc. Geny zoptymalizowanego czynnika VIII
SG11201811704SA (en) 2016-07-13 2019-01-30 Biogen Ma Inc Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
KR20190090827A (ko) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
WO2018144623A1 (en) 2017-01-31 2018-08-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
CA3094112A1 (en) 2018-03-28 2019-10-03 Bristol-Myers Squibb Company Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US20210238289A1 (en) 2018-06-04 2021-08-05 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
TW202328174A (zh) 2021-08-23 2023-07-16 美商百歐維拉提夫治療公司 以反向末端重覆序列製造封閉dna
AR126846A1 (es) 2021-08-23 2023-11-22 Bioverativ Therapeutics Inc Genes del factor viii optimizados
KR20240067122A (ko) 2021-09-30 2024-05-16 바이오버라티브 테라퓨틱스 인크. 감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same

Also Published As

Publication number Publication date
DE669986T1 (de) 1996-10-10
EP0669986B1 (en) 2003-04-09
DE69332859T2 (de) 2003-12-18
US5733779A (en) 1998-03-31
DE69332859D1 (de) 2003-05-15
ATE236987T1 (de) 2003-04-15
PT669986E (pt) 2003-08-29
EP0669986A1 (en) 1995-09-06
CA2149326A1 (en) 1994-05-26
US6159730A (en) 2000-12-12
ES2088838T3 (es) 2004-01-01
US6017733A (en) 2000-01-25
CA2149326C (en) 2007-04-17
ES2088838T1 (es) 1996-10-01

Similar Documents

Publication Publication Date Title
DK0669986T3 (da) Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr
WO1994011523A3 (en) Fully impaired consensus kozac sequences for mammalian expression
Miyata et al. Nucleotide sequence divergence of mouse immunoglobulin gamma 1 and gamma 2b chain genes and the hypothesis of intervening sequence-mediated domain transfer.
WO1992001049A3 (en) Cd53 cell surface antigen and use thereof
NO983102D0 (no) Uttrykk og forsterkning av sekvenselementer (EASE) for eukaryote ekspresjonssystemer
DK0597960T3 (da) Behandling af cellepopulationer
SE8007998L (sv) Forfarande for framstellning av interferon
ATE66693T1 (de) Rekombinante dns-sequenzen, diese enthaltende vektoren und verfahren zur verwendung derselben.
DK1056873T3 (da) Fremgangsmåder til produktion af et polypeptid i en Bacillus-celle
ES8602119A1 (es) Metodo para preparar inmunoglobulinas en celulas hospedantes recombinantes
HUP9904203A2 (hu) Eljárás hosszú, ismétlődő DNS-szekvenciák stabil klónozására
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
Ogawa et al. Molecular cloning, sequence analysis, and expression in Escherichia coli of the cDNA for guanidinoacetate methyltransferase from rat liver.
AU4835696A (en) Amplifying sequences, vectors comprising these sequences and their uses in compositions for the expression of nucleotide sequences in transfected cells, therapeutic and vaccine applications.
DE69936919D1 (en) Fy7 polymerase
Barcak et al. Comparative nucleotide sequence analysis of growth-rate-regulated gnd alleles from natural isolates of Escherichia coli and from Salmonella typhimurium LT-2
FR2685004B1 (da)
YU200091A (sh) Delecioni mutanti ahasarezistentni na herbicide
TW343997B (en) Mutant AOX2 promoter, vector carrying same, transformant, and production of heterologous protein
Weissbach A chronicle of DNA methylation (1948–1975)
DK0981537T3 (da) Smitsom klon af humant parainfluenzavirus type 3
ATE281523T1 (de) Acarbose-biosynthesegene aus actinoplanes sp., verfahren zu ihrer isolierung sowie ihrer verwendung
Goldfarb et al. Transcription in vitro of an isolated fragment of bacteriophage T4 genome
ID24649A (id) Replikon virus epstein-barr kompak
Wynford‐Thomas et al. Suppression of transformation and immortality in human/chinese hamster fibroblast hybrids—a model for suppressor gene isolation